Hims & Hers gains as FDA panel endorses peptide BPC-157
Seeking Alpha ·
Shares of Hims & Hers Health ( HIMS ) rose more than 10% on Thursday after an FDA advisory panel voted to include a popular peptide known as BPC-157 in a list of molecules that compounding pharmacies use to make customized treatments.
AI 시장 분석
Shares of Hims & Hers Health surged over 10% on Thursday, driven by the FDA advisory committee's recommendation to approve the peptide BPC-157. This move establishes a legal foundation for the company to utilize popular ingredients in compounding treatments. Investors expect future regulatory easing to act as a positive momentum for earnings growth.
상승 영향
- Biotechnology — The FDA advisory committee's recommendation to approve the peptide BPC-157 is expected to accelerate the expansion of the customized treatment portfolio.
AI가 생성한 분석으로 투자 자문이 아닙니다.
DYAX Investor Sentiment
Bullish (Long) 39% · Bearish (Short) 61%
398 participants
Related News
- Ryder forecasts 2026 comparable EPS of $14.40-$14.80 as used vehicle gains outlook rises to about $40M
- Quest Diagnostics projects $11.95B-$12.05B 2026 revenue while raising EPS outlook again
- First Industrial lifts 2026 NAREIT FFO outlook to $3.08-$3.16 as it starts a $77M Philadelphia development
- First Resource Bank GAAP EPS of $0.92, revenue of $8.53M
- StandardAero selected by GE to support engines for U.K. military helicopter fleet
- OpenAI says Health in ChatGPT now available to US users
